PDF(Pubmed)
Abstract：
Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD). It is a humanized monoclonal antibody targeting cluster of differentiation 19 (CD19). Common adverse reactions include urinary tract infections, nasopharyngitis, arthralgia, infusion reactions, headaches and a decrease in immunoglobulin levels. Here, we present a case of an NMOSD patient who experienced transient hyperCKaemia after the use of inebilizumab. The adverse reactions of this very rare monoclonal antibody drug improved after discontinuation.
摘要：
Inebilizumab是批准用于水通道蛋白-4免疫球蛋白G-血清阳性视神经脊髓炎谱系障碍（NMOSD）的维持治疗的单克隆抗体之一。它是靶向分化簇19(CD19)的人源化单克隆抗体。常见的不良反应包括尿路感染，鼻咽炎,关节痛,输液反应,头痛和免疫球蛋白水平下降。这里,我们介绍了一例NMOSD患者,该患者在使用血胆珠单抗后出现短暂性高CKa血症.这种非常罕见的单克隆抗体药物的不良反应在停药后有所改善。
